Zobrazeno 1 - 10
of 1 314
pro vyhledávání: '"Hepatic impairment"'
Autor:
Wei Yin, Pranab Mitra, Veronique Copalu, Thomas C. Marbury, Juan Carlos Rondon, Eric J. Lawitz, Valerie Lloyd, Mike Baratta, Mahnaz Asgharnejad, Tom Hui, Yasir Khan
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract This phase 1, open‐label, three‐arm study (NCT05098054) compared the pharmacokinetics and safety of soticlestat (TAK‐935) in participants with hepatic impairment. Participants aged ≥18 to
Externí odkaz:
https://doaj.org/article/f54bfb954336446f92cc2bd5c1afa903
Publikováno v:
Metabolites, Vol 14, Iss 9, p 471 (2024)
Nalbuphine (NAL) is a mixed κ-agonist/μ-antagonist opioid with extensive first-pass metabolism. A phase 1 open-label study was conducted to characterize the pharmacokinetics (PKs) of NAL and select metabolites following single oral doses of NAL ext
Externí odkaz:
https://doaj.org/article/a2246a2e93ae4384bca4a04e32f3edc8
Autor:
Dragos Gabriel Iancu, Andreea Varga, Liviu Cristescu, Robert Adrian Dumbrava, Florin Stoica, Diana Andreea Moldovan, Radu Adrian Suteu, Ioan Tilea
Publikováno v:
Diagnostics, Vol 14, Iss 16, p 1824 (2024)
Background: Pulmonary hypertension (PH) is a global health issue that has profound medical and research implications. Methods: This retrospective study examined changes in renal and liver function, as well as lipid metabolism, over a 12-month period
Externí odkaz:
https://doaj.org/article/fd818c0793674668a157eb1b275648af
Publikováno v:
Pharmaceutics, Vol 16, Iss 7, p 855 (2024)
The evaluation of transporter-mediated drug–drug interactions (DDIs) during drug development and post-approval contributes to benefit–risk assessment and helps formulate clinical management strategies. The use of endogenous biomarkers, which are
Externí odkaz:
https://doaj.org/article/7cb18cf515ea4c15b52a3e04238439de
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
National Journal of Medical Research, Vol 13, Iss 04 (2023)
Background: Petrol Pump attendants (PPA) in India wear a variety of safety gear, including as overalls, masks, and gloves. It is still entirely unknown if they can effectively protect vulnerable organs like the liver and kidney. The study's objective
Externí odkaz:
https://doaj.org/article/b7a132e4af594eefa6e389997ec3bbf2
Autor:
Kit Wun Kathy Cheung, Yang Tang, Doreen Anders, Teresa Barata, Astrid Scalori, Priya Agarwal, Rucha Sane, Sravanthi Cheeti
Publikováno v:
Pharmaceutics, Vol 16, Iss 4, p 564 (2024)
Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely
Externí odkaz:
https://doaj.org/article/36e760d984da4103856adc19adf5013b
Publikováno v:
Clinical Pharmacology: Advances and Applications, Vol Volume 15, Pp 9-19 (2023)
Yiming Cheng,1 Ying Ye,1 Allison Gaudy,1 Atalanta Ghosh,2 Yongjun Xue,3 Alice Wang,1 Simon Zhou,1 Yan Li1 1Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA; 2Global Biometrics and Data Sciences, Bristol Myers Squibb,
Externí odkaz:
https://doaj.org/article/5cd3f02d399d417c8102ca8bd64a478d
Autor:
Yue Hu, Xiaojiao Li, Jingrui Liu, Hong Chen, Wenbo Zheng, Hong Zhang, Min Wu, Cuiyun Li, Xiaoxue Zhu, Jinfeng Lou, Pangke Yan, Nan Wu, Xiao Liu, Shiping Ma, Xu Wang, Yanhua Ding, Chengluan Xuan
Publikováno v:
Annals of Medicine, Vol 54, Iss 1, Pp 2758-2769 (2022)
Background The primary objective of this study was to investigate if hepatic impairment alters the safety, pharmacokinetics, and pharmacodynamics of HSK3486.Research design and methods This was a clinical trial of HSK3486 in subjects with normal hepa
Externí odkaz:
https://doaj.org/article/47b2fb3c1cea48198dbee99496937eed
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 16, Pp 3947-3955 (2022)
Dehua Zhao, Xiaoqing Long, Jisheng Wang Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan, People’s Republic of ChinaCorrespondence: Dehua Zhao; Jisheng Wang, Email zhaoyaoshi0566@163.
Externí odkaz:
https://doaj.org/article/921fcca6e7ae43ccaea043544089827e